Celecoxib was a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibited cyclooxygenase-2 (COX-2). It was used to reduce pain and inflammation. The U.S. Food and Drug Administration first approved it in 1998 for osteoarthritis and rheumatoid arthritis. Later approvals covered additional conditions, including acute pain, primary dysmenorrhea, ankylosing spondylitis, and juvenile rheumatoid arthritis. Approved uses differed by product and country.
BRAND NAMES
Celebrex
Celebra
Elyxyb
Vyscoxa
Onsenal
ZyCEL
Celedol
MECHANISM OF ACTION
Celecoxib mainly blocked COX-2, an enzyme involved in producing prostaglandins. These substances contributed to pain, fever, and inflammation, so reducing their production helped relieve those symptoms. At usual therapeutic concentrations, celecoxib had less effect on COX-1 than on COX-2. Clinical trials found that it did not reduce platelet aggregation or prolong bleeding time. It nevertheless carried NSAID-related risks, including serious cardiovascular and gastrointestinal events.
PHARMACOKINETICS
Absorption
After an oral capsule dose, celecoxib reached peak blood concentrations in about 3 hours. A high-fat meal delayed the peak by about 1–2 hours and increased total drug exposure by roughly 10–20%. Its effective half-life under fasting conditions was about 11 hours.
Distribution
About 97% of celecoxib in the blood was bound to proteins, mainly albumin. Its apparent volume of distribution was about 400 L, which indicated that the drug spread extensively into body tissues.
Metabolism
Celecoxib was metabolized mainly in the liver by the CYP2C9 enzyme. The metabolites identified in plasma did not inhibit COX-1 or COX-2.
Elimination
The body eliminated celecoxib mainly after liver metabolism. Less than 3% of the dose was recovered unchanged in urine and feces. After a radiolabeled dose, about 57% was recovered in feces and 27% in urine, mostly as metabolites.
PHARMACODYNAMICS
Celecoxib was an NSAID that acted mainly by blocking COX-2. This lowered the formation of prostaglandins, substances that contributed to pain, inflammation and fever. At treatment doses, celecoxib did not substantially inhibit platelets, so it did not serve as a replacement for aspirin used to prevent cardiovascular events. Changes in prostaglandin activity could also lead to fluid retention and affect the kidneys.
ADMINISTRATION
The medicine was swallowed by mouth. Label directions allowed doses to be taken with or without meals. For patients who could not swallow capsules, the instructions described emptying the capsule onto a teaspoon of cool or room-temperature applesauce and swallowing it right away with water. Patients were directed to use the smallest dose that controlled symptoms for the shortest appropriate time.
DOSAGE AND STRENGTHS
U.S. capsule strengths included 50 mg, 100 mg, 200 mg and 400 mg, though availability varied by manufacturer. The dosage recommendations were provided to qualified healthcare professionals to guide clinical care. Treatment was individualized based on the condition being treated, the patient’s age and body weight, kidney and liver function, coexisting medical conditions, other medications being taken, and response to therapy. The full prescribing information was reviewed before treatment began or any dose was adjusted.
DRUG INTERACTIONS
Celecoxib may increase bleeding risk when taken with anticoagulants, antiplatelet medicines, aspirin, SSRIs, or SNRIs. It may also reduce the effectiveness of some blood pressure medicines and diuretics, and increase the risk of kidney problems—especially in older, dehydrated, or kidney-impaired people taking ACE inhibitors or ARBs. Celecoxib can raise lithium and digoxin levels and increase methotrexate side effects. Some medicines, including fluconazole and rifampin, can also change celecoxib levels. Ask a prescriber before changing prescribed low-dose aspirin or combining these medicines.
FOOD INTERACTIONS
Standard celecoxib capsules could generally be taken with or without food at doses up to 200 mg twice daily. A high fat meal delayed the time to peak blood levels by about 1–2 hours and increased total absorption by roughly 10–20%. The prescribing information advised taking 400 mg twice daily with food. Aluminum- or magnesium-containing antacids lowered celecoxib levels. Directions could differ by product, so the label for the specific formulation was relevant.
CONTRAINDICATIONS
Celecoxib capsules were contraindicated for people who:
Had an allergy to celecoxib or its ingredients, or a history of allergic reactions to sulfonamides.
Were undergoing coronary artery bypass graft (CABG) surgery.
The prescribing information also warned of serious heart and blood vessel events, stomach or intestinal bleeding, and risks during pregnancy. NSAID use was generally limited from about 20 weeks of pregnancy unless a clinician advised it, and avoided from about 30 weeks.
SIDE EFFECTS
Commonly reported effects included abdominal pain, diarrhea, indigestion, gas, swelling in the arms or legs, dizziness, and rash.
Serious effects included stomach ulcers or bleeding, heart attack or stroke, high blood pressure, worsening heart failure, kidney or liver injury, severe allergic reactions, and severe skin reactions.
Urgent medical help was advised for chest pain, difficulty breathing, sudden weakness or trouble speaking, vomiting blood, black stools, swelling of the face or throat, or a severe rash or blistering.
OVERDOSE
An overdose could cause sleepiness, nausea, vomiting, or stomach pain. More serious effects could include gastrointestinal bleeding, high blood pressure, acute kidney failure, slowed breathing, or coma. There was no specific antidote.
If an overdose had occurred, the advice was to seek emergency medical care or contact a local poison service promptly, even if the person felt well. Inducing vomiting or waiting for symptoms was not advised.
TOXICITY
Celecoxib could cause serious heart, gastrointestinal, kidney, liver, and skin toxicity. Risk could increase with higher doses or longer use, and could be greater for older adults and people with a history of ulcers, heart or kidney disease, dehydration, or certain interacting medicines. The prescribing advice was to use it only as directed, at the lowest effective dose for the shortest recommended time.